Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Leadership Pricing Debate Policy

BIO Stalwart Greenwood Announces Departure

  • Analysis

Executive Summary

Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.

You may also be interested in...



Next BIO CEO Needs Political Savvy, Greenwood Says

A scientist may provide a certain look, but understanding politics is more important to ensuring the health of the pharma industry, the outgoing president and CEO of BIO said in an interview.

Outgoing BIO CEO Focuses On Out-Of-Pocket Costs As Solution To Drug Pricing Woes

In interview with the Pink Sheet, Jim Greenwood also worries about President Trump promoting drug pricing policies that could hinder innovation.

Rx Patent Reform Gets Renewed Interest From GOP As Alternative To Price Negotiation

A Republican congressman and witness discuss shortened IP protections while criticizing Nancy Pelosi's drug price negotiation plan.

Table

View full table

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Related Companies

Tags:
Leadership Pricing Debate Policy
UsernamePublicRestriction

Register

PS140978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By